Home Magazines Editors-in-Chief FAQs Contact Us

Utility of CA-125 in interval surgery


Obstetrics & Gynecology International Journal
Bianchi F,<sup>1,3</sup> Boixart A,<sup>2</sup> Dallochio MP,<sup>3</sup> Wiedemann M,<sup>4</sup> Codoni MJ,<sup>3</sup> Garcia Balcarce T,<sup>3</sup> Ramilo T,<sup>3</sup> Camargo A<sup>5</sup>

PDF Full Text

Abstract

Standard treatment for advanced-stage epithelial ovarian cancer (EOC) consists of debulking surgery and chemotherapy. Progression-free survival (PFS) and overall survival (OS) correlate with residual tumor burden after debulking surgery. There are situations in which it is not feasible to perform the aforementioned surgery, requiring neoadjuvant chemotherapy (NACT) with eventual interval surgery.
The objective of the study was to retrospectively evaluate patients who were not plausible for primary cytoreduction, analyzing the value of CA-125 pre and post neoadjuvant chemotherapy and its suitability between these values and the surgical result.

Keywords

interval surgery, chemotherapy, cytoreduction, ovarian cancer

Testimonials